{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:14:53Z","timestamp":1783646093011,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jaad.2026.01.024","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:57:47Z","timestamp":1769011067000},"page":"78-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Infection risk among psoriasis biologic-new users: A cohort study on the French National Health Data System"],"prefix":"10.1016","volume":"95","author":[{"given":"Tran Trong Khoi","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tat-Thang","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2026.01.024_bib1","article-title":"The burden of psoriasis: a call for awareness","volume":"38","year":"2021","journal-title":"eClinicalMedicine"},{"issue":"3","key":"10.1016\/j.jaad.2026.01.024_bib3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2026.01.024_bib4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","article-title":"Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.: cause-specific mortality in patients with severe psoriasis","volume":"163","author":"Abuabara","year":"2010","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.01.024_bib5","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"10201","key":"10.1016\/j.jaad.2026.01.024_bib6","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"10273","key":"10.1016\/j.jaad.2026.01.024_bib7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jaad.2026.01.024_bib8","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2026.01.024_bib9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jamadermatol.2018.0183","article-title":"Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR","volume":"154","author":"Mason","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.01.024_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials","volume":"148","author":"Carretero","year":"2012","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.01.024_bib11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","article-title":"Association between biologics use and risk of serious infection in patients with psoriasis","volume":"157","author":"Penso","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.01.024_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2026.01.024_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/jvc2.35","article-title":"Risk of respiratory tract infections and serious infections in psoriasis patients treated with biologics: results from the BioCAPTURE registry","volume":"1","author":"Van Der Schoot","year":"2022","journal-title":"JEADV Clin Pract"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.024_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjd.16809","article-title":"Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-na\u00efve patients from the French National Health Insurance database (SNIIRAM)","volume":"180","author":"Sbidian","year":"2019","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2026.01.024_bib15","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2026.01.024_bib16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/pds.4006","article-title":"Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database","volume":"25","author":"Sahli","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.jaad.2026.01.024_bib18","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F","article-title":"Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians","volume":"19","author":"Carpenter","year":"2000","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.jaad.2026.01.024_bib19","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.21037\/jtd.2017.05.34","article-title":"A general introduction to adjustment for multiple comparisons","volume":"9","author":"Chen","year":"2017","journal-title":"J Thorac Dis"},{"issue":"2","key":"10.1016\/j.jaad.2026.01.024_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bjd.17036","article-title":"Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"180","author":"Yiu","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.01.024_bib21","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/bjd.14068","article-title":"Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States","volume":"173","author":"Kimball","year":"2015","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2026.01.024_bib22","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/acr.24630","article-title":"Risk of hospitalization for serious infection after initiation of ustekinumab or other biologics in patients with psoriasis or psoriatic arthritis","volume":"74","author":"Jin","year":"2022","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jaad.2026.01.024_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/20406223231206225","article-title":"Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Chiu","year":"2023","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"10.1016\/j.jaad.2026.01.024_bib24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/ije\/18.1.269","article-title":"Ecological bias, confounding, and effect modification","volume":"18","author":"Greenland","year":"1989","journal-title":"Int J Epidemiol"},{"issue":"4","key":"10.1016\/j.jaad.2026.01.024_bib25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.det.2021.05.010","article-title":"The use of biologics during the COVID-19 pandemic","volume":"39","author":"Jones","year":"2021","journal-title":"Dermatol Clin"},{"issue":"4","key":"10.1016\/j.jaad.2026.01.024_bib26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/1740774515588097","article-title":"Applying the intention-to-treat principle in practice: guidance on handling randomisation errors","volume":"12","author":"Yelland","year":"2015","journal-title":"Clin Trials"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226000630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226000630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:59:05Z","timestamp":1783645145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226000630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0190962226000630"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.01.024","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infection risk among psoriasis biologic-new users: A cohort study on the French National Health Data System","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}